Navigation Links
RainDance Appoints Becker Chief Commercial Officer
Date:3/18/2008

GUILFORD, Conn., March 18 /PRNewswire/ -- RainDance Technologies, Inc., a developer of NanoReactor droplet-based microfluidic technology, today announced the appointment of Stephen E. Becker as Vice President, Commercial Officer, effective immediately.

"Mr. Becker will be responsible for continuing the growth of the company's commercial operations as it prepares for the launch of its first life science offering," said Chris McNary, President and Chief Executive Officer, RainDance Technologies. "These duties will include the continued development of the sales channels, leading customer service and support programs, and development of the strategic marketing plan."

The RainDance platform combines emulsion-based droplets and microfluidics to enable a host of existing applications in the company's nano-scale format, including genomic analysis, cell-based assays, and single molecule detection. Samples such as cells, nucleic acids, proteins, beads, and chemical compounds are encapsulated in individual micron-sized droplets on assay-specific microfludic chips. Since each droplet is the equivalent of a well in a microtiter plate, the RainDance platform can process and analyze up to 10,000 samples per second with unparalleled accuracy.

Becker joins RainDance from Agilent Technologies, where he served as Senior Sales Manager in the company's Americas Field Operations. There, he led the commercial introduction of novel genetic and epigenetic microarray assays that achieved over 20% growth rates in 2006 and 2007 in the research and molecular diagnostics markets. At GE Healthcare (formerly Amersham Pharmacia Biotech), Becker held several senior management assignments, including Director, Gene and Protein Discovery, and Director, Business Support. He also held sales management positions at Spectrum Chemical Manufacturing Corporation and Curtin Matheson Scientific, Inc. Becker received a bachelor's degree in biology from St. Mary's College of California.

"The RainDance droplet technology is a new tool that will allow scientists to accelerate their research through the advantages provided by nano-scale reactions at unparalleled assay speeds in the life science, diagnostic, and industrial markets," said McNary. "Mr. Becker's broad experiences will help us develop best-in-class commercial processes that support the introduction of our exciting technology."

About RainDance Technologies, Inc.

RainDance Technologies, Inc., is a biomedical technology company devoted to developing and commercializing a proprietary droplet-based microfluidics platform. The core of our technology is the generation of stable, nano-liter sized droplets that act as the functional equivalent of a test tube, or a well on a microtiter plate. Each droplet can encapsulate an individual sample of cells or reagents for both preparative and analytical life science and chemical analysis applications. RainDance recognizes that the rate and scale of research are accelerating dynamically, and for researchers to keep pace with these demands, they need the benefits of high-quality individualized reactions generated on a massive scale. Our vision is to be the worldwide leader in massively parallel sample processing and analytical solutions that provide a new standard of data quality.

RainDance has developed instrumentation and disposable microfluidic circuits that enable researchers to generate experimental results faster than existing methodologies, with increased throughput and decreased experimental variability. We will provide these tools to academic and commercial researchers working on a variety of basic and applied research applications. Our proprietary emulsion chemistries and microfluidic manufacturing process allow our platform to miniaturize many biological and chemical assays. These same core attributes will allow the RainDance platform to perform biological and chemical applications previously unimaginable or unaffordable using conventional laboratory or microfluidic techniques.

The company was founded in 2004 by scientists from Harvard University, the Medical Research Centre in Cambridge, and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board, including three Nobel Prize winners (Jean-Marie Lehn, Sir Aaron Klug, and Dr. Richard Roberts) and Sir Gregory Winter.

The company's areas of focus include genomics, proteomics, cell biology, and molecular diagnostics. Importantly, we continue to expand our capabilities by partnering with the research community and commercial development partners to generate novel applications of the core RainDance technology.

For more information, please visit http://www.raindancetechnologies.com.


'/>"/>
SOURCE RainDance Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. RainDance Technologies Appoints McNary President and CEO
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... , ... Parallel 6 , the leading software as a service (SaaS) ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication between ... Using the CONSULT module, patients and physicians can schedule a face to face virtual ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
Breaking Biology News(10 mins):